Profound Medical Appoints Dr. Arun Menawat to Board of Directors

TORONTO, Oct. 17, 2014 (GLOBE NEWSWIRE) -- Profound Medical Inc., a medical device company developing and commercializing a unique, minimally invasive treatment for prostate cancer, today announced the addition of Dr. Arun Menawat to its Board of Directors.

Dr. Menawat is currently President and Chief Executive Officer of Novadaq Technologies Inc. (Nasdaq:NVDQ) (TSX:NDQ) a leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures. Dr. Menawat has been Novadaq's President and CEO since April 2003. Previously, he held senior management positions at Cedara Software Corp., Tenneco, Inc. and Hercules, Inc. His educational background includes a Ph.D. in Chemical Engineering from the University of Maryland, College Park, MD, including research in Biomedical Engineering from the National Institute of Health, Bethesda, MD. Dr. Menawat also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University in Evanston, IL.

"We are pleased to welcome Dr. Menawat to our Board. His successful career in growing companies will be a great compliment to our Board," said Steve Plymale, Chief Executive Officer of Profound Medical. "Dr. Menawat will be a valuable resource to the Company, and to me personally, as we continue to grow and scale our business."

Profound Medical recently completed enrollment of its Phase I safety and feasibility TULSA ("Transurethral ULtraSound Ablation") trial. "I am delighted to join Profound and look forward to working closely with the Board and management team to further the Company's goals in the commercialization of its technology," said Dr. Menawat.

About Profound Medical

Profound Medical is a Canadian medical device company that is developing and commercializing a unique, minimally invasive treatment for prostate cancer. The Company's novel technology combines Magnetic Resonance Imaging ("MRI") guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. This method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The company recently completed enrollment in its 30 patient multi-jurisdictional TULSA safety and feasibility trial. 


Contact Data